Download PDF
Thromb Haemost 1999; 82(04): 1370-1371
DOI: 10.1055/s-0037-1614400
Letters to the Editor
Schattauer GmbH

Albumin-Free Formulated Recombinant Factor VIII Preparations – How Big a Step Forward?

H. Pollmann
1   From the University Munster Children’s Hospital, Hemophilia Centre, Munster, Germany, USA
,
L. Aledort
2   Mt. Sinai Medical Center, New York, USA
› Author Affiliations
Further Information

Publication History

Received 24 June 1999

Accepted 24 June 1999

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453-9.
    CrossrefPubMedGoogle Scholar
  • 2 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
    PubMedGoogle Scholar
  • 3 Aygören-Pürsün E, Scharrer I. German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 White GC, Courter S, Bray GL, Lee M, Gomperts ED. Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Schulman S, Gitel S, Martinowitz U. Stability of factor VIII concentrates after reconstitution. Am J Hematol 1994; 45: 217-23.
    CrossrefPubMedGoogle Scholar
  • 6 McClelland DBL. Safety of human albumin as a constituent of biologic therapeutic products. Transfusion 1998; 38: 690-9.
    CrossrefPubMedGoogle Scholar
  • 7 Baxter T, Black D, Birks D. New variant Creutzfeldt-Jakob disease and treatment of haemophlia. Lancet 1998; 351: 600-1.
    PubMedGoogle Scholar
  • 8 Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood?. Emerg Infect Dis 1997; 3: 155-63.
    CrossrefPubMedGoogle Scholar
  • 9 Österberg T, Fatouros A, Mikaelsson M. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ. Pharm Res 1997; 14: 892-8.
    CrossrefPubMedGoogle Scholar
  • 10 Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1998; 80: 624-31.
    Article in Thieme ConnectPubMedGoogle Scholar